Crotty Dylan Bram sold $145K of SYK (indirect holdings)

Crotty Dylan Bram (Group President) sold 441 indirectly-held shares of STRYKER CORP (SYK) at $328.60 ($0.14M total) on 2026-08-21.

Original reporting
SEC EDGAR · Crotty Dylan Bram
Published Aug 26, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The disclosed sale is routine and does not provide a new trading decision.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming earnings or product announcements could give context to the sale.

Relevance 4/10Novelty 4/10Timing: post-market 2026-08-21

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Group President Crotty Dylan Bram sold 441 shares of SYK for $144,914.80 via open-market transaction on 2026-08-21.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and insider holds 6,102 shares after the transaction.

Market effects

None

None

None

Counterpoint

Insider sales sometimes precede negative news, but no other catalyst is indicated.

Key entities

  • Stryker Corp

    Medical device manufacturer (ticker SYK).

  • Crotty Dylan Bram

    Group President of Stryker Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.